Anti-tsg101 antibodies and their uses for treatment of viral infections
AssigneeFunctional Genetics, Inc.
InventorsLimin Li, Michael Kinch, Michael Goldblatt
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.
Claims18
A method for inhibiting virus infection in a mammalian subject, comprising providing to said subject an effective amount of an anti-TSG101 antibody, wherein said antibody binds TSG101 present on cells of said subject which may become infected with said virus.
An anti-TSG101 monoclonal antibody, said antibody binds to a TSG101 C-terminal region consisting of an amino acid sequence recited in SEQ ID NO:3.
A monoclonal antibody that binds to TSG101 selected from the group consisting of antibodies C, D1, E, 3G1 and CB8.
A pharmaceutical composition for inhibiting viral infection in a mammal, comprising:
- 1) an effective amount of an anti-TSG101 antibody;
- and
- 2) a pharmaceutically acceptable carrier,
- wherein said anti-TSG101 antibody binds to an epitope within the TSG101 C-terminal region consisting of the amino acid sequence recited in SEQ ID NO:3.
A pharmaceutical composition for inhibiting viral infection in a mammal, comprising:
- 1) an effective amount of an anti-TSG101 antibody;
- and
- 2) a pharmaceutically acceptable carrier,
- wherein said anti-TSG101 antibody is selected from the group consisting of antibodies C, D1, E, 3G1 and CB8.
Dependencies are inferred from the claim text.